CL2007002201A1 - Compuestos derivados de eteres heterociclicos substituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la ansiedad, depresion, trastorno obsesivo compulsivo, bulimia, trastornos del panico. - Google Patents
Compuestos derivados de eteres heterociclicos substituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la ansiedad, depresion, trastorno obsesivo compulsivo, bulimia, trastornos del panico.Info
- Publication number
- CL2007002201A1 CL2007002201A1 CL200702201A CL2007002201A CL2007002201A1 CL 2007002201 A1 CL2007002201 A1 CL 2007002201A1 CL 200702201 A CL200702201 A CL 200702201A CL 2007002201 A CL2007002201 A CL 2007002201A CL 2007002201 A1 CL2007002201 A1 CL 2007002201A1
- Authority
- CL
- Chile
- Prior art keywords
- compound
- heterociclic
- eters
- bulimia
- anxiety
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 3
- 208000019901 Anxiety disease Diseases 0.000 title 1
- 208000032841 Bulimia Diseases 0.000 title 1
- 206010006550 Bulimia nervosa Diseases 0.000 title 1
- 230000036506 anxiety Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 208000019906 panic disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83365206P | 2006-07-27 | 2006-07-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007002201A1 true CL2007002201A1 (es) | 2008-02-08 |
Family
ID=38895951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200702201A CL2007002201A1 (es) | 2006-07-27 | 2007-07-27 | Compuestos derivados de eteres heterociclicos substituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la ansiedad, depresion, trastorno obsesivo compulsivo, bulimia, trastornos del panico. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080027056A1 (es) |
| EP (1) | EP2069328A2 (es) |
| JP (1) | JP2009544726A (es) |
| KR (1) | KR20090043497A (es) |
| CN (1) | CN101495470A (es) |
| AR (1) | AR062113A1 (es) |
| AU (1) | AU2007276744A1 (es) |
| BR (1) | BRPI0714615A2 (es) |
| CA (1) | CA2659192A1 (es) |
| CL (1) | CL2007002201A1 (es) |
| MX (1) | MX2009000762A (es) |
| NO (1) | NO20090193L (es) |
| PE (1) | PE20080678A1 (es) |
| TW (1) | TW200817361A (es) |
| WO (1) | WO2008014247A2 (es) |
| ZA (1) | ZA200900613B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8026257B2 (en) * | 2007-07-11 | 2011-09-27 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
| US20090018163A1 (en) * | 2007-07-11 | 2009-01-15 | Bristol-Myers Squibb Company | Substituted Heterocyclic Ethers and Their Use in CNS Disorders |
| US7632861B2 (en) * | 2007-11-13 | 2009-12-15 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
| WO2009096941A1 (en) * | 2008-01-28 | 2009-08-06 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in cns disorders |
| SG187286A1 (en) | 2011-07-29 | 2013-02-28 | Smart Communications Inc | System and method for activating a mobile device to initiate a communication |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994010165A1 (en) * | 1992-10-28 | 1994-05-11 | Merck Sharp & Dohme Limited | 4-arylmethyloxymethyl piperidines as tachykinin antagonists |
| US7041682B2 (en) * | 2002-07-03 | 2006-05-09 | Schering Corporation | NK1 antagonists |
| AU2003258937A1 (en) * | 2002-09-09 | 2004-03-29 | Astrazeneca Ab | Naphthyl ether compounds and their use |
| US20070249607A1 (en) * | 2006-04-17 | 2007-10-25 | Bristol-Myers Squibb Company | Nk-1 and serotonin transporter inhibitors |
-
2007
- 2007-07-24 WO PCT/US2007/074198 patent/WO2008014247A2/en not_active Ceased
- 2007-07-24 CA CA002659192A patent/CA2659192A1/en not_active Abandoned
- 2007-07-24 CN CNA2007800283776A patent/CN101495470A/zh active Pending
- 2007-07-24 BR BRPI0714615-9A patent/BRPI0714615A2/pt not_active Application Discontinuation
- 2007-07-24 EP EP07813277A patent/EP2069328A2/en not_active Withdrawn
- 2007-07-24 MX MX2009000762A patent/MX2009000762A/es not_active Application Discontinuation
- 2007-07-24 KR KR1020097001572A patent/KR20090043497A/ko not_active Withdrawn
- 2007-07-24 US US11/782,045 patent/US20080027056A1/en not_active Abandoned
- 2007-07-24 AU AU2007276744A patent/AU2007276744A1/en not_active Abandoned
- 2007-07-24 JP JP2009521946A patent/JP2009544726A/ja active Pending
- 2007-07-26 PE PE2007000983A patent/PE20080678A1/es not_active Application Discontinuation
- 2007-07-26 AR ARP070103320A patent/AR062113A1/es not_active Application Discontinuation
- 2007-07-27 TW TW096127612A patent/TW200817361A/zh unknown
- 2007-07-27 CL CL200702201A patent/CL2007002201A1/es unknown
-
2009
- 2009-01-13 NO NO20090193A patent/NO20090193L/no not_active Application Discontinuation
- 2009-01-26 ZA ZA200900613A patent/ZA200900613B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2659192A1 (en) | 2008-01-31 |
| WO2008014247A3 (en) | 2008-03-20 |
| KR20090043497A (ko) | 2009-05-06 |
| ZA200900613B (en) | 2010-04-28 |
| AU2007276744A1 (en) | 2008-01-31 |
| NO20090193L (no) | 2009-01-29 |
| AR062113A1 (es) | 2008-10-15 |
| JP2009544726A (ja) | 2009-12-17 |
| US20080027056A1 (en) | 2008-01-31 |
| TW200817361A (en) | 2008-04-16 |
| MX2009000762A (es) | 2009-01-28 |
| BRPI0714615A2 (pt) | 2013-06-18 |
| CN101495470A (zh) | 2009-07-29 |
| WO2008014247A2 (en) | 2008-01-31 |
| EP2069328A2 (en) | 2009-06-17 |
| PE20080678A1 (es) | 2008-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
| CL2008000691A1 (es) | Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades. | |
| CL2007003202A1 (es) | Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular. | |
| CL2007002578A1 (es) | Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer. | |
| CL2007003352A1 (es) | Compuestos derivados de heteromonociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso cen | |
| CL2007003797A1 (es) | Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades. | |
| CL2008000224A1 (es) | Composicion farmaceutica que comprende un compuesto derivado glucopiranosilo; y uso para el tratamiento de uno o mas trastornos neurodegenerativos. | |
| CL2007003138A1 (es) | Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
| CL2007002424A1 (es) | Compuestos derivados de isoxazolidina; composicion farmaceutica que comprende a dicho compuesto, util para el tratamiento de trastornos asociados con hiperproliferacion como cancer. | |
| BRPI0909768A2 (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto | |
| CL2007003049A1 (es) | Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos. | |
| CL2007003495A1 (es) | Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer. | |
| PT2056814E (pt) | Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase | |
| CL2007003244A1 (es) | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. | |
| CR20110103A (es) | Heteroarilos sustituidos | |
| CL2009000171A1 (es) | Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion. | |
| CL2007002920A1 (es) | Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos. | |
| CL2007002479A1 (es) | Compuestos derivados de pirazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos tromboembolicos. | |
| CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
| CL2007003299A1 (es) | Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
| CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
| CL2007001881A1 (es) | Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos. | |
| BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. | |
| BRPI0815591A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio. | |
| CL2008002708A1 (es) | Compuestos derivados de azaciclilisoquinolinona e isoindolinona, antagonistas de histamina-3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuestos; y uso del compuesto para el tratamiento de un trastorno cognitivo, |